Frankfurt - Delayed Quote • EUR
Zealand Pharma A/S (22Z.F)
As of April 18 at 12:51 PM GMT+2. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2018) | Next Qtr. (Jun 2018) | Current Year (2018) | Next Year (2019) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2018) | Next Qtr. (Jun 2018) | Current Year (2018) | Next Year (2019) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | -- | 2.27M | 5.69M | 6.08M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | 5.69M |
| Sales Growth (year/est) | -- | -- | -- | 6.80% |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2018) | Next Qtr. (Jun 2018) | Current Year (2018) | Next Year (2019) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.39 | -0.61 | -2.37 | -1.49 |
| 30 Days Ago | -0.39 | -0.61 | -2.37 | -1.49 |
| 60 Days Ago | -0.39 | -0.61 | -2.37 | -1.49 |
| 90 Days Ago | -0.39 | -0.61 | -2.37 | -1.49 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2018) | Next Qtr. (Jun 2018) | Current Year (2018) | Next Year (2019) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | 22Z.F | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.80% |
| Next Qtr. | -- | -- | -- | 9.60% |
| Current Year | -- | -- | -- | 4.50% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
No Fair Value available for this ticker
Related Tickers
DNTH Dianthus Therapeutics, Inc.
23.63
+1.24%
IPA ImmunoPrecise Antibodies Ltd.
1.2400
-2.36%
ACIU AC Immune SA
2.3800
-1.65%
VOR Vor Biopharma Inc.
1.6800
-2.89%
NOV.DE Novo Nordisk A/S
115.72
-0.62%
GMAB Genmab A/S
28.33
-0.70%
TERN Terns Pharmaceuticals, Inc.
4.5900
+1.10%
NMRA Neumora Therapeutics, Inc.
10.55
+0.76%
ATHE Alterity Therapeutics Limited
2.1400
+3.38%
XFOR X4 Pharmaceuticals, Inc.
1.2000
+0.42%